Healthcare / Drug Manufacturers - GeneralKOSDAQ
$3490.00
+95.00 (+2.80%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $3.8B · quality 52.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
53/100
C
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$37.8B
P/E
5.8x
↓EV/EBITDA
3.4x
↓ROE
7.8%
↑Gross Margin
42.6%
↓Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-7.9%
FCF CAGR
—
FCF margin
20.2%
FCF / Net income
1.94x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $62.51B · net income $6.51B · FCF $12.63B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $62.51B | $62.51B | $73.00B | $81.37B | $79.98B |
| Net Income | $6.51B | $6.51B | $3.00B | $-4.92B | $11.81B |
| EBITDA | $9.77B | $9.77B | $7.07B | $10.02B | $16.07B |
| EPS | 602.00 | 602.00 | 278.00 | -456.00 | 1095.00 |
| Gross Margin | 42.6% | 42.6% | 47.1% | 45.9% | 43.2% |
| Operating Margin | 11.1% | 11.1% | 12.5% | 22.2% | 17.9% |
| Net Margin | 10.4% | 10.4% | 4.1% | -6.0% | 14.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 6.63 | 6.63 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $12.63B | $12.63B | $3.83B | $-2.64B | $-564.4M |
| Returns | |||||
| ROE | 7.8% | 7.8% | 3.8% | -6.4% | 13.9% |
| Valuation | |||||
| P/E | 5.80 | 5.80 | 16.89 | — | 7.53 |
| EV/EBITDA | 3.37 | 3.37 | 6.59 | 6.62 | 5.33 |
| P/B | 0.45 | 0.45 | 0.65 | 1.01 | 1.05 |
| Growth & Yield | |||||
| Revenue Growth | -14.4% | -14.4% | -10.3% | 1.7% | — |
| EPS Growth | 116.5% | 116.5% | 161.0% | -141.6% | — |
| Dividend Yield | 5.2% | 5.2% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-19.9%
EPS terminal req.
$309.68
Spread vs growth
136.4%
5Y implied EPS CAGR
-9.0%
EPS terminal req.
$374.71
Spread vs growth
125.6%
10Y implied EPS CAGR
0.0%
EPS terminal req.
$603.48
Spread vs growth
116.5%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-21.3%
Start / end P/E
17.1x → 5.8x
EPS bridge
278.00 → 602.00
Residual
-77.0%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.